Keystone Law has advised UK investors Fink Family Office and Science Angel Syndicate on their investment into UK-based medical device company QV Bioelectronics.
Securing a total of £2 million in funding from new and existing leading deep tech investors, QV Bioelectronics is developing the first-of-its-kind electric field therapy implant to treat the most common and aggressive types of brain tumours. The funding will help support expanded pre-clinical studies to evaluate the GRACE implant’s safety and efficacy, and the completion of device design before it enters the clinical phase of development.
GRACE is set to be implanted in patients already undergoing surgery to maximise patient safety and cost-effectiveness. Working alongside the UK’s leading neurosurgeons, QV has ensured GRACE meets the needs of clinicians and fits seamlessly into existing patient treatment pathways.
Keystone advised on the growth capital investment and was led by corporate partner Nadim Zaman assisted by Albert Mennen.
Lord Stanley Fink said:
“I am thrilled to be investing in QV Bio’s latest round under the stewardship of trusted advisers Keystone Law. Having suffered from a brain tumour over a decade ago, this is a cause extremely close to my heart. There has been limited progress in brain cancer survival rates over the past decade when compared to the advances in other cancers and I hope QV Bio will help bridge this gap.”
Nadim Zaman added:
“It is always a pleasure to collaborate with Fink Family Office and on this occasion teaming up with Science Angel Syndicate, which will be instrumental in helping the development of this important therapy in the UK and beyond.”